How'd you fix 23andMe's revenue issues in 2026?
Direct Answer 23andMe's 2026 turnaround pivots from DTC-only consumer genetics to a B2B therapeutics + data monetization hybrid model, fixing the broken one-time-kit CAC problem by: (1) ruthless cost discipline post-Regeneron acquisition, (…
Read full answer ↗